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Heart failureThe mammalian heart expresses two closely related natriuretic peptide (NP) hormones, atrial natriuretic fac-
tor (ANF) and brain natriuretic peptide (BNP). The excretion of the NPs and the expression of their genes
strongly respond to a variety of cardiovascular disorders. NPs act to increase natriuresis and decrease vascular
resistance, thereby decreasing blood volume, systemic blood pressure and afterload. Plasma levels of BNP are
used as diagnostic and prognostic markers for hypertrophy and heart failure (HF), and both ANF and BNP are
widely used in biomedical research to assess the hypertrophic response in cell culture or the development of
HF related diseases in animal models. Moreover, ANF and BNP are used as speciﬁc markers for the differen-
tiating working myocardium in the developing heart, and the ANF promoter serves as platform to investigate
gene regulatory networks during heart development and disease. However, despite decades of research, the
mechanisms regulating the NP genes during development and disease are not well understood. Here we re-
view current knowledge on the regulation of expression of the genes for ANF and BNP and their role as bio-
markers, and give future directions to identify the in vivo regulatory mechanisms. This article is part of a
Special Issue entitled: Heart failure pathogenesis and emerging diagnostic and therapeutic interventions.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The heart of mammals expresses atrial natriuretic factor (ANF,
ANP, a-type natriuretic peptide) and brain natriuretic peptide (BNP,
b-type natriuretic peptide). Both proteins and their encoding genes
have been identiﬁed decades ago [1–6], and their various physiologi-
cal functions and expression in different organs have been studied ex-
tensively [7–11]. The overall effect of their function is to lower blood
volume, reducing cardiac output and systemic blood pressure. In
studies of vertebrate cardiogenesis, ANF and BNP have proven to be
very useful and sensitive markers that discriminate chamber myocar-
dium of the atria and the ventricles (positive) from primary,
non-chamber myocardium such as the atrioventricular canal and
pacemaker tissues (negative) [12]. Use of ANF regulation as a model
system has led to the discovery of transcriptional mechanisms that
control chamber and conduction system development [11,13].
Ventricular expression of the genes for ANF and BNP is down-
regulated after birth (Fig. 1A–D). However, in the adult mammalian
heart, their levels strongly increase during hypertrophy and HF
(Fig. 1E, F). HF occurs when the heart is unable to provide sufﬁcient
pump action to distribute blood ﬂow to meet the needs of the body,
and is the end stage of a variety of cardiac diseases. HF is a common,ure pathogenesis and emerging
hristoffels).
rights reserved.disabling condition that can lead to death. Development of HF can re-
sult from hypertension causing increased ventricular wall stress and
left ventricular hypertrophy, an important intermediate stage in tran-
sition to HF [14]. Other causes of HF include myocardial infarction
(MI) and muscle loss, cardiomyopathy (the deterioration of muscle
function), valve insufﬁciency and single-gene mutations [15–24].
Plasma levels of BNP and the N-terminal fragment of its prohormone,
NT-proBNP, are used as diagnostic and prognostic markers for hyper-
trophy and HF [25]. Normal levels rule out acute HF in the emergency
setting, whereas increased levels are associated with ventricular dys-
function. ANF is widely used in biomedical research to assess the hy-
pertrophic response in cell culture or the development of HF-related
diseases in animal models.
While a large body of knowledge is available on ANF and BNP
function, and on conditions in which they are induced, little is
known about the actual transcriptional mechanisms responsible for
their regulation and induction in the heart. For example, the induc-
tion of ANF in the ventricle during hypertrophy is considered to be
part of the induction of a fetal gene program [26]. This fetal program
is a common feature of different pathological conditions including hy-
pertrophy, ischemia, hypoxia, atrophy, where the heart experiences
extensive remodeling and returns from utilization of fatty acids to
carbohydrate for energy provision in increased hypoxic conditions.
Other hallmarks are the induction of ANF and BNP, early response
genes, such as c-myc and c-fos, and switches in isoform expression
of genes for metabolic enzymes and sarcomeric proteins (e.g. induc-
tion ofMyh7 and Acta1 in mouse). Triggered by increased mechanical
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Fig. 1. Expression of ANF and BNP mRNA in sections of mouse embryonic, adult
and diseased hearts. A, B. In E14.5 mouse embryos, ANF and BNP are expressed in
both atrial and trabecular ventricular myocardium. The atrioventricular canal and out-
ﬂow tract myocardium do not express ANF/BNP. C, D. Expression of ANF in the adult
heart is restricted to the atria and the Purkinje ﬁbers of ventricular myocardium,
whereas BNP is expressed in atrial myocardium and in ventricular myocardium in
a transmural gradient from the endocardial side. E, F. ANF and BNP mRNA are
upregulated in the ventricles during hypertrophy. G, H. ANF and BNP are reactivated
in theborder zoneaftermyocardial infarction. ra, right atria; la, left atria; rv, right ventricle;
lv, left ventricle; ivs, interventricular septum; iz, infarct zone; bz, border zone.
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ensure cell survival under stress [27]. The regulatory DNA sequences
of ANF controlling fetal ventricular expression on the one hand, and
induction during disease on the other are different [28,29] and have
not yet been identiﬁed. As a consequence, the transcriptional mecha-
nisms remain to be elucidated. Insight into these mechanisms will
help us to understand the pathology of hypertrophy and HF at the
molecular level, and to understand the link between phenotype and
ANF/BNP expression to use these molecules as biomarkers for cardio-
vascular disease more effectively. In this review we will discuss cur-
rent insight into the expression patterns of ANF and BNP during
development and cardiac disease, and the underlying mechanisms
of gene regulation, focusing on the regulatory DNA sequences and
interacting factors.
2. ANF and BNP expression proﬁles during development and disease
ANF was the ﬁrst natriuretic peptide to be identiﬁed and puriﬁed
from atrial extracts in 1981, when it was shown to increase natriure-
sis, diuresis and vasodilation [30]. But the spectrum of action was not
limited to cardiovascular and renal systems. Receptors for ANF were
identiﬁed in different organs including the kidney, lung, liver, adrenal
cortex, and the small intestines, where it could regulate salt and
water balance as well [31]. Moreover, ANF receptors [31] as well as
bioactive peptide were also found in the brain [32–34]. Extensive
work on the puriﬁcation of a variety of active peptides in the 1980s
revealed that in addition to ANF the brain contains another NP, there-
fore called BNP [2]. One of the actions of NPs in the brain is to inhibit
release of adrenocorticotropic hormone, thereby decreasing aldoste-
rone release and enhancing natriuresis. Furthermore, the ANF-ergic
neurons inhibit arginine vasopressin release leading to diuresis [35].
Therefore, NPs expressed in the brain also serve to maintain optimal
liquid homeostasis. Although isolated from the brain, BNP is predom-
inantly expressed in the heart ventricles and mimics the pharmaco-
logical activity of ANF in regulation of blood pressure. Isolated ANF
and BNP proteins were found to have a remarkably similar struc-
ture [2,30]. These NPs are encoded by natriuretic peptide A (Nppa)
and -B (Nppb), respectively, which are positioned adjacent to each
other and in close proximity (b15 kilo base pairs (kbp) distance) in
the vertebrate genome [6,36,37]. Both genes are expressed in speciﬁc
patterns in the developing and adult heart, and induced in particular
cardiovascular pathological conditions.
2.1. Temporal expression patterns of NPs in the heart
Expression of ANF is initiated in the tubular murine heart (mouse
embryonic day (E) 8) at the level of the future left ventricle. Thereaf-
ter, it is activated in the developing atria and the ventricles of the
looping and ballooning heart [12,38]. When compact myocardium
of the ventricles begins to form between E10-12, expression of
ANF becomes restricted to the trabeculated layer, higher in the left
ventricle than in the right. The expression of ANF is limited to differ-
entiating chamber (future working) myocardium. The myocardium
ﬂanking the chambers, the sinus venosus, including the sinus node,
the atrioventricular canal including the future atrioventricular node,
and the outﬂow tract never express ANF [12]. Because of this proper-
ty, ANF has been used extensively as a marker for differentiating
chamber myocardium during cardiogenesis, which has led to the
identiﬁcation of transcriptional mechanisms for chamber and con-
duction system development [39]. In human fetuses, ANF mRNA is
more abundant in the atria than in the ventricles [40], whereas in
the ovine fetal heart atrial expression is lower than that of the ventri-
cles during the last two-third of the gestation period [41].
In mammals during gestation and after birth, ventricular ANF ex-
pression decreases from 50% of atrial expression in human and 4%
in mouse fetuses to about 1% in adult mammalian hearts [29,42,43].
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ventricular conduction system [44]. Progressive decline in ventricular
ANF expression during development was reported in Xenopus, mouse
and sheep [41,45]. However, in contrast to mammals, adult zebraﬁsh
and Xenopus frogs maintain ANF expression in their trabecular ventri-
cles [46]. Taken together, the relative contribution of ventricular ANF
is more pronounced in the embryo than in the adult heart.
The spatio-temporal expression proﬁle of BNP mimics that of ANF
[47]. BNP expression in the embryonic mouse heart exhibits a peak of
expression at midgestation (E12.5) with the ventricles being the
dominant source of expression [48]. Neither BNP mRNA nor BNP pep-
tide was detected in human 12–17 week fetuses [49,50]. After birth
BNP mRNA level increased in both mouse atrium and ventricle, but
still did not reach the mid-gestation level [48]. In rat, bovine and
human hearts ANF and BNP were restricted to the ventricular conduc-
tion system [51–53].
Four C-type natriuretic peptide (CNP) genes, CNP-1–4, were
generated by chromosomal duplications. Of these, CNP-3 was tandemly
duplicated to give rise to ANF and BNP before the divergence of tetra-
pods and teleosts. Later in evolution, speciﬁc lineages of CNP genes
were lost in different vertebrate classes. For example, frogs have lost
CNP-1 and CNP-2 [54]. Chicken (birds) has lost the ANF gene, but
retained BNP and their predecessor CNP-3. Mammals have lost the
CNP-3 gene, but retained CNP-4 as the only CNP gene. Although CNP
was not detected in the mouse heart [55] or in the human fetal, normal
adult and failing myocardium with Northern blot analysis [49], differ-
ence in plasma CNP level between aortic root and coronary sinus indi-
cates its production in the human heart [56]. Moreover, CNP was
detected in the rat and pig cardiomyocytes and endothelial cells within
the heart [57].ANF
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Fig. 2. Response of ANF and BNP in different animal models of cardiomyopathy [59,60,62,67,7
blue and immunoreactive proteins in the ventricles are presented in green. The measured l2.2. Induction of NP levels and gene expression in response to heart
disease
Upon cardiac cell stress, ANF and BNP are rapidly released from
pre-stored granules. ANF and BNP are stored in the same secretory
granules in the atria [58] and their concentration in the blood is
expected to rise simultaneously and to the same extent. Indeed, stud-
ies show synchronous elevation of plasma ANF and BNP during the
time-course of acute volume or pressure overload [59–61] as well as
presence of both elevated ANF and BNP in chronic models of hyper-
tension [62,63] (Fig. 2). However, in these studies, the rise of BNP in
plasma in the period of 2–24 h after induction of volume overload is
inferior compared to that of ANF [59,64]. More short-term experi-
ments were performed with isolated atria or ventricles to estimate
secretion of NPs in minutes after stimulation, which showed that
both ANF and BNP were acutely secreted with a peak at about
20–30 min after atrial pacing [65,66] and already in 1–5 min after
ventricular stimulation [67]. These results indicate the ability of
both atrial and ventricular myocytes to rapidly respond to stress.
The mechanisms of predominantly atrial secretion of ANF after me-
chanical or neurohumoral stimulation are discussed by Thibault et
al. [68]. Long term experiments with chronic overload revealed
some differences in atrial and ventricular secretion of the NPs. Secretion
of ANF from the overloaded left ventricle of spontaneously hypertensive
rats (SHR) was accompanied by the decrease in ventricular concentra-
tion of immunoreactive ANF, whereas atrial protein concentration was
not changed compared to the control rats. In vitro studies with the iso-
lated hearts showed that hypertensive ventricles contributed 28% of
the total ANF released, while normotensive ventricles contributed only
8%. These experiments suggest that excess ANF is released from theBNP
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pertension, right atrial content as well as whole heart content of ANF
was decreased [70], indicating atrial secretion of ANF. The difference
can be explained by the differences in complex regulation of NPs release
from the secretory granules and their de novo synthesis from an in-
creased pool of mRNA.
In addition to the greater response of ANF to stress, its plasma
level is also more sensitive to hemodynamic changes in the heart.
Volume overload in dogs caused by furosemide showed rapid and
gradual elevation of plasma ANF, which correlated with heart rate
and left ventricular end-diastolic pressure (LVEDP), and was rapidly
diminished 1 h after induced diuresis. In contrast, while elevated to
a lesser extent, BNP could not diminish to the original level in 1 h
after preload reduction [61]. Supporting this idea, the ACE inhibitor
alacepril administered in patients with congestive heart failure was
shown to decrease plasma ANF already 1 h after treatment, whereas
it took more than 6 h for plasma BNP to decrease [87]. These ﬁndings
are in agreement with the view that secretion and clearance of ANF
and BNP are regulated differently [88]. The regulatory mechanism in-
volves several neuro-humoral factors including renin–angiotensin
system. In one of the hypertension models in rat, overexpression of
the renin gene led to impaired induction of BNP release after volume
or pressure overload [62]. Thus, plasma ANF level may be a more sen-
sitive marker than BNP in fast response to hemodynamic changes in
the blood.
Stress not only induces secretion of stored NPs, but also enhances
their gene expression both in atrial and ventricular myocardium.
Upregulation of ANF and BNP is initiated in the cardiomyocytes
subjected to stress and, therefore, can be localized in the myocardium
surrounding only right ventricular lumen after pulmonary trunk banding
[89], only left ventricular lumen after aortic banding (Fig. 1E, F) or in the
border zone after coronary artery ligation (Fig. 1G, H). Temporal regula-
tion of ANF and BNP enhanced expression is also different in various con-
ditions of cardiac disorders (Fig. 2). After myocardial infarction induced
by isoproterenol injections in rats, BNF mRNA was upregulated in both
ventricles at 18 h after injection, whereas ANF mRNA level gradually in-
creased until signiﬁcant levels 3 days after isoproterenol administration
[59]. The same trend was observed in rats with aortocaval shunt, where
both ANF and BNP plasma levels were steady elevated at 1 day and
7 days after surgery. Expression of BNF was induced only at 1 day after
volume overload, but upregulation of ANF mRNA followed that of BNP
only in 7 days after surgery [59,80]. Acute ventricular overload after MI
[60,80], hypertension [86] and volume overload [80] leads to rapid and
sometimes transient upregulation of BNP mRNA in the affected ventric-
ular myocardium, whereas ANF upregulation follows BNP at later time
points. These studies present BNP as a marker of acute myocardial stress
on the gene expression level. However,measurements of ANF andBNP in
some animal models of volume overload are contradictory—both ANF
and BNP mRNA can be upregulated at the same time in the border
zone ofMI [90] or in the right ventricle of the hearts with pulmonary hy-
pertension caused by aortocaval shunt before ventricular hypertrophy
becomes evident [91]. BNP also showed increase in mRNA level during
the transition from compensated to overt HF, since its expression
was increased only during ﬁbrosis development at the late stages of hy-
pertrophy [85]. In patients with chronic volume overload caused by
regurgitant heart valvular lesion, BNPmRNAwas upregulated in the ven-
tricles, whereas ANF mRNA level was similar to the control group [78].
Therefore BNP gene expression can serve as a marker of hypertrophy
progression.
In the embryonic heart, NPs respond similar to pathological stim-
uli compared to the adult heart. Experiments with fetal rats, sheep
and goats demonstrated that ANP plasma level was increased not
only after stimulation with vasoconstrictors such as phenylephrine
(PE), angiotensin II (AngII) and endotelin-1 (ET-1) [10], but also
responded to systemic stress such as volume overload [92] and hyp-
oxia [93,94]. Human fetuses increased their plasma concentration ofANF in anemic, acidemic, and hydropic conditions [95]. Both adult
and embryonic mice deﬁcient for the NPR-A receptor developed con-
centric hypertrophy, and fetuses produced more ANF and BNP mRNA
already at E15.5 [96].
Taken together, completely different stimuli leading to cardiac hy-
pertrophy, remodeling and HF are accompanied by increased ANF and
BNPmRNA levels in the heart and protein levels in the heart and plas-
ma. How such different pathophysiological stimuli cause similar in-
duction of ANF and BNP expression, however, is not well understood.
2.3. ANF and BNP as markers of heart failure
For decades, plasma levels of the NPs have been used as a diagnostic
marker in clinical settings tomonitor the severity of hypertrophy andHF
events [25]. ANF appeared to be less prognostic then BNP because of
its shorter half-life in the blood [97,98]. Furthermore, levels of the
amino-terminal fragment of the precursor peptide (NT-proBNP) were
shown to be a more accurate marker in early diagnosis of HF [99] and
more stable in frozen blood samples [100] compared to the mature
carboxy-terminal BNP hormone. This makes NT-proBNP a widely used
and reliable clinical marker. More recently, mid regional pro-ANP
(MR-proANP) was evaluated for detection of cardiovascular diseases
[101]. Together, both peptides are used as prognostic and diagnostic
markers in many cardiovascular abnormalities such as hypertension,
HF, left ventricular diastolic dysfunction, valvular stenosis and coronary
artery disease [25]. BNP and NT-proBNP were elevated not only in the
general symptomatic population, but also in patients with structural
congenital heart defects such as systemic right ventricle, tetralogy of
Fallot and univentricular heart, although the prognostic value of the
markers in these cases has to be conﬁrmed in a larger cohort [102]. Obe-
sity is an independent risk factor for hypertension, left ventricular hy-
pertrophy and HF. Studies linking obesity and hypertension suggest
that activation of sympathetic and renin–angiotensin systems in obese
individuals result in renalwater and sodium retention, blood volumeex-
pansion and hypertension [103]. In parallel, lipid accumulation in the
heart inhibits NPs mRNA and protein synthesis [104], the adipose tissue
exhibits elevated expression of the clearance receptor NPR-C. Conse-
quently, low level of ANF andBNP reduces NP-dependent lipolysis in ad-
ipocytes, therefore perpetuating obesity and sustaining decreased
plasma level of NPs [105]. Although hypertension is marked by elevated
levels of ANF and BNP, both healthy subjects and patients with cardio-
vascular diseases can have lower levels of measured NPs, which in this
case predicts development of diabetes [103,106]. This paradox is a result
of a complex physiological neuro-humoral response of the heart and
was named ‘natriuretic handicap’ [105].
Although ANF and BNP are produced by the heart in response to
a broad range of heart-related disorders, a differential diagnosis still
requires assays in addition to NP level measurements. Combining
myocytes injury marker cardiac troponin T and myocardial stretch
marker NT-proBNP improves prognosis of mortality risk in patients
with chronic HF [107]. Stressed myocardium is susceptible not only
to mechanical stretch and injury, but also to inﬂammation and ven-
tricular remodeling, and can be associated with renal dysfunction.
Over the last decades, novel sets of biomarkers have emerged that
represent speciﬁc molecular pathways and physiological processes
[108,109]. Such multimarker approaches will help clinicians to phe-
notype and predict a particular disease, monitor and guide the treat-
ment of HF patients.
3. Mechanisms of ANF and BNP gene regulation
Several signal transduction pathways have been identiﬁed that
mediate the response of ANF and BNP to various stimuli. In the vast
majority of cases, the proximal promoter sequences, just upstream
of the transcription start site, were found to contain transcription fac-
tor binding elements or response elements that are involved in the
2407I.A. Sergeeva, V.M. Christoffels / Biochimica et Biophysica Acta 1832 (2013) 2403–2413transcriptional response. In this section we summarize these path-
ways and elements, in the next section the in vivo relevance of
these elements will be discussed.
3.1. Regulation of ANF and BNP expression by mechanical stress
Soon after the normal function of the heart changes due to hyper-
tension, valve insufﬁciency or loss ofmyocardialmuscle after infarction,
cardiomyocytes experience additional load and stretch. Mechanisms of
stretch-activated expression of ANF and BNP were studied in isolated
cardiomyocytes, and atrial and ventricular preparation to separate
the response of cardiomyocytes to strain from systemic response in-
duced by neurohumoral factors. Mechanical stretch induces ANF, BNP
and skeletal alpha-actin mRNA expression in neonatal ventricular
cardiomyocytes [110] and atrial preparations [65,110,111]. The signal
from mechanically-strained extracellular matrix propagates through
the integrins and a cascade of intracellular kinases to activate p38
MAP kinase and NF-kappa-B [111–114] and promote binding of the lat-
ter to shear stress-responsive elements (SSREs) in the BNP promoter. In
parallel with direct activation of BNP through p38 MAPK, mechanical
strain stimulated synthesis of AngII and ET-1, which induced the
ERK-signaling pathway acting on the BNP promoter [113,115]. Involve-
ment of integrins and FAK (focal adhesion kinase) was also shown for
activation of ANF expression both in vitro [116] and in vivo [117]. The
sequences responsible for the stretch- and FAK-mediated activation
are located within the 700 bp rANF promoter [118].
Two GATA binding sites at−84 and−95 bp as well as an NKE el-
ement at −387 bp in the rBNP promoter were found to mediate the
stretch-induced response in ventricular myocytes and overloaded
ventricles [110,119,120]. Mechanical strain activates ET-1 synthesis
in cardiomyocytes [113], which in turn causes induction of ANF and
BNP expression [111]. Increased GATA4 binding activity induced by
pressure overload was inhibited by ET-1 receptor antagonist bosartan,
suggesting an autocrine/paracrine regulatory mechanism after overload
in ventricles [119].
3.2. Regulation of ANF and BNP expression through growth factors
Transforming growth factor beta (TGFβ) regulates multiple cellular
processes in both adult and embryonic organisms including heart devel-
opment and hypertrophy. Ligand binding leads to phosphorylation of
receptor-regulated SMAD proteins, their association with SMAD4 and
translocation of this transcriptional complex to the nucleus. TGFβ stim-
ulates ANF and BNP mRNA expression in neonatal cardiac myocytes
[121] and in rat hearts after MI [122]. The signal is transferred to
the transcriptional machinery by downstream targets of TGFβ, TAK1-
MKK3/6-p38MAPK. Later it was shown that the BNP promoter is differ-
entially regulated by p38 isoforms. While p38α acts through AP-1 sites
at −373 bp in the rBNP promoter, p38β activates BNP expression
through the−90/−81 bp GATA sites [123].
Fibroblast growth factor (FGF) and insulin-like growth factor
(IGF-1) are known to be involved in the organization of cytoskeletal
and contractile structures of cardiomyocytes [124]. IGF-1, a circulato-
ry hormone produced mostly by the liver, promotes growth of
many cell types. However, it was shown to inhibit cardiomyocyte
elongation and cardiac hypertrophy, and control Ca2+ homeostasis
[125,126]. In accordance with these functions during HF progression,
IGF-1 was shown to downregulate ANF expression in rat ventricular
cardiomyocytes both in culture [127] and in vivo [128], whereas
FGF increased ANF mRNA levels [127]. However, contradictory stud-
ies demonstrated pro-hypertrophic effects of IGF-1. Similar to its
function in skeletal muscle hypertrophy [129], IGF-1 promoted hy-
pertrophy of adult rat ventricular myocytes and induced ANF mRNA
expression through a calcineurin-dependent mechanism and activa-
tion of the transcription factor Mef2C [130,131].3.3. Role of G protein-coupled receptors in NP gene regulation
Several neurohumoral factors are involved in the hypertrophy re-
sponse of the heart, including activation of ANF and BNP expression
and secretion. AngII, ET-1, norepinephrine and epinephrine function
through G protein-coupled receptors AT1 and AT2, ET-A and α- and
β-adrenergic receptors, respectively. AngII is the main effector of the
renin–angiotensin system, andwas found to be involved in hypertrophy
remodeling through activation of AT1 receptors on cardiomyocytes, ﬁ-
broblasts and smooth muscle cells within the heart, which triggers G
protein-coupled and non-G protein-coupled signaling pathways includ-
ing MAP kinases (ERK 1/2, JNK, p38MAPK), receptor tyrosine kinases
(PDGF, EGFR, insulin receptor), non-receptor tyrosine kinases (Src,
JAK/STAT, FAK) and reactive oxygen species [132–135]. Recently, the
AT2 receptor has received more attention because of its protective role
in regeneration and repair processes involving c-kit(+) progenitor
cells after MI [136]. However, AT2 was not involved in hypertrophy-
related upregulation of ANF, since its expression in AT2−/− mice after
aortic banding was not different from that of wild-type mice [137]. Be-
sides direct activation of ANF expression through the AT1 receptor,
AngII stimulated production of TGFβ in cardiacmyocytes and ﬁbroblasts
[138], thereby inﬂuencing the regulation of NPs through TGFβ-GATA4
pathway [139]. AngII also stimulated ET-1, another pro-hypertrophic
agent in the heart [140].
Vasoconstricting peptide ET-1 is produced primarily by the endo-
thelium, but also by cardiomyocytes. Mechanical stretch induces
upregulation of the ET-A receptor and ET converting enzyme-1 in
stretched atrial myocardium, which in turn leads to enhanced ET-1
signaling and activation of ANF and BNP expression through stimula-
tion of Ca2+/calmodulin-dependent kinase II (CaMKII), extracellular
signal-regulated kinase (ERK) and possible inhibition of transcrip-
tional repressor REST activity at the NRSE sites [111,141,142]. Normally,
REST in complex with HDACs maintains low level of acetylation at the
NRSE regions within the promoter of BNP and the 3′-UTR of ANF. After
ET-1 stimulation, the level of H3 and H4 histone acetylation increased
within ANF and BNP promoters [142] and around NRSE in the 3′-UTR
of ANF [143], thereby increasing the activity of ANF and BNP transcrip-
tion. Moreover, ET-1 activates binding of Yin Yang 1 (YY1) at position
−62 bp in the hBNP promoter [144] and enhances cooperation be-
tween GATA4 and SRF, which interact with the −137/109 bp region
in the rANF promoter [145].
Catecholamine hormones epinephrine and norepinephrine pro-
duced by the adrenal medulla stimulate the sympathetic nervous sys-
tem, resulting in increased heart rate, muscle contraction, cardiac
output and blood pressure. Adrenergic agonists phenylephrine (PE)
and isoproterenol (ISO) are widely used to study the activation of
NP expression during hypertrophy through adrenergic receptors α
and β (ARα and ARβ), respectively [146,147]. The diversity of G pro-
teins coupled to AR, activation of second messengers (IP3, DAG and
cAMP) and protein kinases (PKC, PKA, MAPK), desensitization of the
receptors and the beneﬁcial role of β-blockers in the treatment of
HF has been reviewed by Barry et al. [148]. Further studies provided
many details regarding canonical and noncanonical activation of ERK1/2
through ARβ [149] and negative regulation of ARα-mediated ANF up-
regulation by ARβ-mediated signaling [150] .
Together, these studies describe the broad range of G protein-
coupled receptors and their effectors on ANF and BNP regulation,
where some of the pathways and DNA binding elements may still
be unknown.
3.4. Other regulators of NP expression
Elevated levels of Ca2+ andCa2+-dependent phosphatase calcineurin
have been reported to play an important role in the development of hy-
pertrophy andHF [151]. L-type Ca2+ channels [152] and transient recep-
tor potential subfamily C proteins (TRPCs) were shown to be involved in
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sion anddevelopment ofHF. Knockdownof TRPC1with siRNAprevented
PE-, ET-1- and AngII-dependent upregulation of ANF and BNP [153].
Ca2+ elevation can also be a secondary effect of rising intracellular Na+
due to the upregulation of the Na+/H+ exchanger (NHE) during hyper-
trophy. Increased Na+ induces the reverse mode of the Na+/Ca2+ ex-
changer (NCX) and increases Ca2+, which in turn induces hypertrophy
[154].
Increased thyroid hormone level is an independent risk factor
for development of hypertrophy and HF. Triiodothyronine (T3) medi-
ates ANF mRNA expression through the Akt/GSK-3beta/mTOR signal-
ing pathway, which was shown to be dependent on AT1 receptors
[155], exhibiting a cross-talk between T3 and renin–angiotensin
systems.
Heart function relies on the balanced status and cross-talk between
hormones, growth factors, signaling peptides and ion homeostasis. For
example, AngII can directly stimulate expression of ANF andBNP through
the AT1 receptors, but is also involved in upregulation of ET-1, which in
turn is able to drive the hypertrophic program through the ET-A recep-
tors on cardiomyocytes. T3 signaling was shown to be dependent on
the AT1 receptor-mediated hypertrophic pathway [155], but also inde-
pendently can activate synthesis of TGFβ in cardiomyocytes and intensify
the effect [156]. Mechanical strain acts dually aswell—direct activation of
mechano-sensitive integrins and upregulation of autocrine hormones
AngII and ET-1 are involved in ANF and BNP production. Thus, any devi-
ations from normal homeostasis can lead to initialization and further ac-
celeration of the hypertrophic program and ANF/BNP production.
4. In vivo mechanisms of ANF and BNP gene regulation: identifying
the regulatory DNA elements
From decades of investigation, the regulation of ANF and BNP
through their promoter elements has yielded a wealth of information
regarding gene regulation during heart development and disease.
However, the in vivo importance of the NP promoter elements was
not well understood. In vivo studies, and especially those using
transgenic reporter animals, proved to be very revealing in the actual
capacities and roles of the NP regulatory sequences, and have provid-
ed reliable information regarding the regulation of ANF and BNP in
development and disease.
The proximal promoter fragments of ANF (0.5 to 3.4 kbp) derived
from various species including human, mouse, rat and frog (Xenopus)
drive expression in the developing and adult atria of transgenic mice
(Fig. 3). Habets et al. showed that the proximal promoter drives cor-
rect developmental expression of ANF in the heart, including activa-
tion in atria and ventricles and repression in the atrioventricular
canal. This repression was found to be mediated by a T-box factor
binding site (element) and an NK2-homeobox element in vivo, recog-
nized by Tbx2 and Nkx2-5, respectively [13]. Moreover, Tbx2 mutants
had atrioventricular canal defects and ectopically expressed ANF in
the atrioventricular canal [157,158], whereas Tbx5 mutants completely
failed to form chambers and to activate ANF [11]. The ANF promoter
has thus been exceptionally useful in identifying themechanism under-
lying atrioventricular canal and chamber development, and indirectly
the development of the conduction system [39]. However, ventricular
expression from this promoter fragment varied strongly between differ-
ent transgenic lines, andon averagewas very low.Moreover, the expres-
sion pattern was not completely recapitulated in transgenic mice—it
was ectopically expressed in the left and right sinus horns [13,29],
mediastinal myocardium and compact ventricular myocardium even
in the context of transcriptionally accessible Hprt locus [29]. Moreover,
perinatal downregulation of the reporter gene in the ventricleswasnon-
speciﬁc or not triggered at all in various independent transgenic lines.
The upregulation of ANF and BNP ventricular expression after
divergent stimuli is commonly referred to as the fetal program. But
how similar is the regulation of ANF and BNP during developmentand disease? One of the ﬁrst in vitro studies showed a positive re-
sponse of both 638 bp and 3003 bp rANF 5′-promoter fragments
after stimulation of cultured cardiomyocytes with PE [167]. More-
over, injection of promoter–reporter plasmids in the ventricles of fail-
ing dog hearts also showed a positive response of these fragments
[162]. These experiments suggested that these fragments contain
stress-response regulatory elements of ANF. Later studies, however,
revealed that this capability is not maintained in vivo, implicating
more distal elements in the induction of ventricular reactivation of
the reporter after TAC [28] (Fig. 3).
In vivo studies of BNP stress-responsive regions revealed that
−408/+100 bp hBNP and −534/+4 bp rBNP promoter fragments
are able to increase luciferase reporter activity after acute MI and AngII
infusion, respectively [139,160]. In both cases, the level of the reporter
activation was consistent with upregulation of endogenous BNP. These
studies addressed the stress-response region of BNP, but the develop-
mental activity proﬁle of the promoter fragments was not investigated,
making it difﬁcult to conclude that all necessary information for BNP
regulation is present in the proximal promoter. The BNP promoter frag-
ment coupled to additional regulatory sequences had very limited activ-
ity in vivo [159]. Consistently, we also found that mouse BNP promoter
fragments in transgenic mice did not show any activity in the hearts of
several independent transgenic mouse lines (unpublished observa-
tions). The data suggest that the BNP promoter contains only a fraction
of the regulatory information of BNP, possibly including response to hy-
pertrophy, and that additional distal regulatory DNA regions are re-
quired to regulate its complete spatio-temporal expression pattern.
Three natriuretic peptide genes have been identiﬁed in verte-
brates that are derived from an ancestral CNP-3 gene by duplication
[54]. Mammals maintained two of these genes, Nppa and Nppb, posi-
tioned at a distance of only a few kbp from each other in the genome.
Upstream of the BNP gene a large non-coding region is present. The
regulatory sequences of ANF and BNP could be present anywhere in
this locus, at distances from a few to hundreds or even thousands of
kbp. Moreover, considering the very similar expression patterns and
hypertrophy responses of ANF and BNP, these genes may share the
same regulatory sequences. Similar examples could be found in the
regulation of expression of other clustered genes such as iroquois
(Irx) genes and the myosin heavy chain (MHC) genes.
The Irx genes are found from nematodes to humans. Comparative
studies propose independent duplication events in ancestors of the
insect and vertebrate lineages, resulting in three-gene clusters.
More recently, the whole ancestral three-gene cluster was duplicated
in vertebrates giving rise to paralogous clusters IrxA and IrxB, located
on different chromosomes. Both clusters display conserved orienta-
tion of the three transcripts and distribution of highly conserved non-
coding regions, playing a role of cis-regulatory elements [168,169].
Physical interaction of the promoters of the ﬁrst two genes in each
cluster suggests co-regulation of these genes and explains their simi-
lar expression pattern, whereas the third genes in the clusters stand
apart and usually have divergent expression patterns [170]. It has
been discussed that the sharing of regulatory elements by the genes
has kept them together in a cluster during long course of vertebrate
evolution [168].
The two cardiac myosin heavy chain (MHC) genes, α- and β-MHC,
form a cluster of adjacently positioned genes formed by a genome dupli-
cation event. The two genes are reciprocally regulated in the ventricle
during development and in adult conditions such as hypothyroidism
and pathological cardiac hypertrophy. The β-MHC is the major isoform
expressed in the fetal ventricle, but is downregulated to very low levels
around birth. In contrast, α-MHC is strongly induced around birth and
becomes the major isoform in the mouse heart (note that in human
β-MHC is themajor isoform in the postnatal ventricle). During conditions
of hypertrophy, hypothyroidism or aging, expression of the two isoforms
is reversed, so that β-MHC is re-expressed in the cardiac myocytes while
α-MHC is downregulated [171]. Their distinct spatio-temporal proﬁles
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but the isoform switch is coordinately regulated by thyroid hormone
and response elements in the promoters. In addition, three miRNAs
encoded by intrones of the MHC genes, miR-208a, miR-208b and
miR-499, regulate a set of transcription factors which modulate thyroid
hormone signaling and govern the MHC switch [172]. Thus the
α-MHC/β-MHC gene cluster contains information required for the coor-
dinated regulation of these genes by shared pathways. The examples of
the Irx clusters and the α-MHC/β-MHC locus suggest that the ANF/BNP
gene locus also harbors cis-regulatory elements simultaneously regulat-
ing ANF and BNP, or that ANF and BNP are coordinatedly regulated by
shared signaling mechanisms or non-coding RNAs.The use of bacterial artiﬁcial chromosomes (BAC) allows the func-
tional testing of over 200 kbp of genomic DNA. Studies with BAC
transgenic mice showed that the regulation of ANF in the developing
heart is controlled by distal regulatory elements in addition to the
basic 0,7 kbp promoter. Fetal ventricular activity was found to require
enhancer(s) between −141 and −27 kbp relative to the ANF gene,
and the ventricular transmural pattern sequences within −27 to
+58 kbp. Interestingly, the stress response region for the transgene
was also found to require the −27 to +58 kbp region [29]. Three
distal elements, −34 kb, −31 kb and −21 kb upstream ANF, were
shown to be involved in ANF regulation. A construct in which all
three fragments were fused provided correct ventricular activity
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pression by theHey2 transcriptional repressor in the compactmyocardi-
um. This −34-31-21-ANF-LacZ construct recapitulated embryonic and
adult expression of ANF, which was dependent on Nkx2.5 expression,
but, consistentlywith theﬁndings of Horsthuis et al. [29] did not contain
regulatory elements that respond to pressure overload and perinatal
heart failure [159].
Regulatory elements of the ANF/BNP gene cluster can probably be
identiﬁed by their co-occupancy by transcription factors and particu-
lar histone modiﬁcations in heart tissue [173,174]. Chromatin immu-
noprecipitation followed by massive parallel sequencing (ChIP-seq)
allows mapping of the sites occupied by these factors across the
whole genome. Promoter regions of ANF and BNP as well as more dis-
tal elements within the locus have been shown to be occupied by
Gata4, Nkx2-5, Tbx3, enhancer-associated factors p300 and Polymer-
ase II in vivo [173,175]. Moreover, ChIP-seq revealed the occupancy of
the Nppa/Nppb by several transcription factors in HL-1 cells [174].
Transcriptional activator Tbx5 in cooperation with Nkx2.5 activates
expression of ANF in the embryonic ventricles [11]. Tbx5 and Tbx3
belong to the same subfamily of the T-box transcription factors
expressed in the heart and were shown to occupy the same binding
sites [173]. Therefore, available Tbx3 ChIP-seq data can be used for
analysis of ANF and BNP regulatory regions (Fig. 3).
Genome-wide association studies of genetic variants associatedwith
levels of NT-proBNP identiﬁed variants in the CLCN6 gene adjacent to
ANF [176]. CLCN6 protein function could inﬂuenceNT-proBNP levels. Al-
ternatively, the CLCN6 region may harbor regulatory sequences for BNP.
We currently use a BAC transgenesis approach to identify the regulatory
sequences, and preliminary data indicates that the region from−141 to
+2 kbp relative to ANF gene contains all information required for cor-
rect spatio-temporal expression of BNP during heart development and
its ventricular upregulation in TAC model of hypertrophy and after MI.
5. Conclusion and future directives
Analysis of ANF expression and regulation during development
of the heart has provided important mechanistic insights into the
development of the chamber myocardium and the conduction system
of the heart. The ANF promoter has proven to be a useful tool
for unraveling the mechanisms of transcriptional regulation in the
heart, showing for example the importance of the T-box factors in
heart patterning. Analysis of transcriptional regulation of ANF and
BNP in different animal models of cardiomyopathy demonstrated
the use of NPs in biomedical research to assess hypertrophic response
in the development of HF, which is in agreement with their extensive
application as biomarkers in a broad range of cardiovascular diseases
in clinical practice. However, the regulation and regulatory sequences
of ANF and BNP proved to be more complex than initially thought.
Proximal regulatory sequences are not sufﬁcient to control either
correct spatio-temporal expression or stress-induced upregulation
of these genes. Future research may focus on the identiﬁcation and
functional analysis of the regulatory sequences of ANF and BNP
involved in these processes in vivo. Chromatin immunoprecipitation-
sequencing and chromatin conformation capture technologies com-
bined with reporter mice should allow the identiﬁcation and functional
assessment of these regulatory sequences in the near future. Thereafter,
the composition of the transcriptional complexes acting through
these sequences and the upstream signaling networks can be identiﬁed,
whichwill provide the insights necessary to effectively use theNP genes
as tools to study disease mechanisms and as predictable biomarkers.
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